Related Experiment Video
Updated: Jul 21, 2025

A Mouse Model of Retinal Ischemia-Reperfusion Injury Through Elevation of Intraocular Pressure
Published on: July 14, 2016
β-Asarone Alleviates High-Glucose-Induced Oxidative Damage via Inhibition of ROS Generation and Inactivation of the
Cheol Park1, Hee-Jae Cha2, Hyun Hwangbo3
1Department Division of Basic Sciences, College of Liberal Studies, Dong-eui University, Busan 47340, Republic of Korea.
Abstract:
Diabetic retinopathy (DR) is the leading cause of vision loss and a major complication of diabetes. Hyperglycemia-induced accumulation of reactive oxygen species (ROS) is an important risk factor for DR. β-asarone, a major component of volatile oil extracted from Acori graminei Rhizoma, exerts antioxidant effects; however, its efficacy in DR remains unknown. In this study, we investigated whether β-asarone inhibits high-glucose (HG)-induced oxidative damage in human retinal pigment epithelial (RPE) ARPE-19 cells. We found that β-asarone significantly alleviated cytotoxicity, apoptosis, and DNA damage in HG-treated ARPE-19 cells via scavenging of ROS generation. β-Asarone also significantly attenuated the excessive accumulation of lactate dehydrogenase and mitochondrial ROS by increasing the manganese superoxide dismutase and glutathione activities. HG conditions markedly increased the release of interleukin (IL)-1β and IL-18 and upregulated their protein expression and activation of the nuclear factor-kappa B (NF-κB) signaling pathway, whereas β-asarone reversed these effects. Moreover, expression levels of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome multiprotein complex molecules, including thioredoxin-interacting protein, NLRP3, apoptosis-associated speck-like protein containing a caspase-recruitment domain, and cysteinyl aspartate-specific proteinase-1, were increased in ARPE-19 cells under HG conditions. However, their expression levels remained similar to those in the control group in the presence of β-asarone. Therefore, β-asarone protects RPE cells from HG-induced injury by blocking ROS generation and NF-κB/NLRP3 inflammasome activation, indicating its potential as a therapeutic agent for DR treatment.
Insights
Beta-asarone protects retinal pigment epithelial cells from high glucose-induced damage by reducing oxidative stress and inhibiting inflammatory pathways. This natural compound shows potential for treating diabetic retinopathy (DR).
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Diabetic retinopathy (DR) is a leading cause of vision loss, linked to hyperglycemia-induced oxidative stress.
- Reactive oxygen species (ROS) play a critical role in DR pathogenesis.
- The therapeutic potential of beta-asarone, an antioxidant from Acori graminei Rhizoma, for DR is unexplored.
Purpose of the Study:
- To investigate the protective effects of beta-asarone against high-glucose (HG)-induced oxidative damage in human retinal pigment epithelial (RPE) cells.
- To elucidate the underlying mechanisms, including ROS scavenging and modulation of inflammatory pathways.
Main Methods:
- ARPE-19 cells were treated with high glucose (HG) with or without beta-asarone.
- Assessed cytotoxicity, apoptosis, DNA damage, and ROS generation.
- Measured lactate dehydrogenase, manganese superoxide dismutase, and glutathione levels.
- Analyzed the expression and activation of inflammatory markers, including IL-1β, IL-18, NF-κB, and NLRP3 inflammasome components.
Main Results:
- Beta-asarone significantly reduced HG-induced cytotoxicity, apoptosis, and DNA damage in RPE cells.
- It effectively scavenged ROS, attenuated lactate dehydrogenase release, and enhanced antioxidant enzyme activities.
- Beta-asarone suppressed the release and activation of IL-1β, IL-18, NF-κB, and NLRP3 inflammasome components.
Conclusions:
- Beta-asarone protects RPE cells from HG-induced injury by inhibiting ROS generation and NF-κB/NLRP3 inflammasome activation.
- These findings suggest beta-asarone holds promise as a potential therapeutic agent for diabetic retinopathy.

